mardi 4 avril 2017

Onco Actu du 4 avril 2017

1. Biologie

How understanding blood vessels and immunity could boost cancer treatment [FierceBiotech]

Hunt for cancer 'tipping point' heats up [Nature]

2.11 Etiologie - Alimentation

Cancer warning over posh crisps as study shows they contain three times recommended levels of acrylamide [The Telegraph]

4. Dépistage, diagnostic et pronostic

Tiny bubbles raise hope for biopsy-free cancer diagnosis [Stanford Medicine]

5. Traitements

Novocure's device-chemo combo boosts survival in pancreatic cancer [FierceBiotech]

5.12 Immunothérapies

Cancer researchers worry immunotherapy may hasten growth of tumors in some patients [STAT]

5.12.1 Immunothérapies - partenariats

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals [The Street]

#AACR17: Fresh from Merck embrace, fast-growing Incyte pivots into a PhIII IDO1/Opdivo tie-up with Bristol-Myers [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Collaboration with academia to be reinforced [EMA]

Gottlieb as FDA commissioner would be music to pharma’s ears [STAT]

Europe must find a new home for its drug regulator — and a way to keep using English [Nature]

5.4 Traitements - Economie

Overcoming Challenges Of Outcomes-Based Contracting For Pharmaceuticals: Early Lessons From The Genentech–Priority Health Pilot [Health Affairs Blog]

Strategies To Address The Challenges Of Outcomes-Based Pricing Agreements For Pharmaceuticals [Health Affairs Blog]

The cost of cancer: new drugs show success at a steep price [Reuters]

5.9 AACR

Stand Up To Cancer Names Top Researchers to $12 Million Dream Team on Colorectal Cancer [AACR]

Stand Up To Cancer Awards Innovative Research Grants in Immuno-oncology to 10 Early-career Scientists [AACR]

“No Time to Stop the Momentum” [Cancer Research Catalyst]

5.9.1 AACR - sein

Triple-negative Breast Cancer Patients Who Responded to Immunotherapy Had Long-term Survival Benefit [AACR]

5.9.3 AACR - mélanome

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma [BMS]

Combination of Nivolumab and Ipilimumab Improved Overall Survival For Advanced Melanoma Patients [AACR]

Bristol-Myers immunotherapy combination extends survival in melanoma [Reuters]

5.9.4 AACR - poumon

Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003 [BMS]

Five-year Survival Rate For Nivolumab-treated Advanced Lung Cancer Patients Much Higher Than Historical Rate [AACR]

For Bristol-Myers, A Victory And A Mystery [Forbes]

5.9.5 AACR - CAR-T

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting [Kite]

Durability of CAR T-cell Therapy Response May Depend on Pretreatment Disease Burden in Leukemia Patients [AACR]

5.9.6 AACR - prostate

Shorter Sleep Duration Is Associated With Increased Risk of Fatal Prostate Cancer in Younger Men [AACR]

5.9.7 AACR - divers

Regular Aspirin Use Is Associated with Lower Cancer Mortality [AACR]

Many Childhood Cancer Survivors Carry Mutations in Cancer Predisposition Genes, Raising Risk of Later Disease [AACR]

5.9.8 AACR - Pharma

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting [Seattle Genetics]

#AACR17 roundup: Bristol-Myers, Merck KGaA and Pfizer in the spotlight, marking progress with checkpoints [EndPoints]

5.9.9 AACR - immunothérapies

Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme [BMS]

Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models [Halozyme]

Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy [AACR]

Avelumab was Safe and Yielded Durable Responses for Patients With Advanced Merkel Cell Carcinoma [AACR]

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types [Cancer Research Catalyst]

Avelumab Becomes First Approved Treatment for Patients with Merkel Cell Carcinoma [NCI]

6.10.1 Politiques (USA)

Biden decries ‘draconian cuts’ to NIH in Trump’s proposed budget [STAT]

Plan to Cut Funding for Biomedical Research Hits Opposition in Congress [NY Times]

6.6 Publications

Journals retract paper, flag two others by cancer doc under investigation [Retraction Watch]